Next Article in Journal
Risk Factors Associated with Low Back Pain among A Group of 1510 Pregnant Women
Previous Article in Journal
The Bluegreen Algae (AFA) Consumption over 48 h Increases the Total Number of Peripheral CD34+ Cells in Healthy Patients: Effect of Short-Term and Long-Term Nutritional Supplementation (Curcumin/AFA) on CD34+ Levels (Blood)
Open AccessReview

An Omics View of Emery–Dreifuss Muscular Dystrophy

INSERM, Center of Research in Myology, Institute of Myology, Sorbonne University, 75013 Paris, France
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2020, 10(2), 50; https://doi.org/10.3390/jpm10020050
Received: 13 May 2020 / Revised: 8 June 2020 / Accepted: 12 June 2020 / Published: 15 June 2020
Recent progress in Omics technologies has started to empower personalized healthcare development at a thorough biomolecular level. Omics have subsidized medical breakthroughs that have started to enter clinical proceedings. The use of this scientific know-how has surfaced as a way to provide a more far-reaching view of the biological mechanisms behind diseases. This review will focus on the discoveries made using Omics and the utility of these approaches for Emery–Dreifuss muscular dystrophy. View Full-Text
Keywords: LMNA; Emery–Dreifuss muscular dystrophy; Omics LMNA; Emery–Dreifuss muscular dystrophy; Omics
MDPI and ACS Style

Vignier, N.; Muchir, A. An Omics View of Emery–Dreifuss Muscular Dystrophy. J. Pers. Med. 2020, 10, 50.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop